Poslední aktualizace :
19/11/2024
Antiaritmikas   Verapamil hydrochloride  
Įpurškimas
Geriamas tirpalas
Tirpalų stabilumas Mišinių stabilumas Stabilumą lemiantys veiksniai Suderinamumas Leidimo būdai Bibliografija pdf
   Cheminė sandara  

Prekinis pavadinimas   Prekinis pavadinimas     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Calaptin Indija
Calovera Indija
Cordilox Didžioji Britanija
Dilacoran Meksikas
Filacard Vokietija
Flamon Šveicarija
Geangin Danija
Isocor Rumunija
Isoptin Australija, Austrija, Egiptas, Graikija, Italija, Jungtinės Amerikos Valstijos, Lenkija, Naujojoje Zelandijoje, Olandija, Portugalija, Saudo Arabija, Švedija, Šveicarija, Vokietija
Isoptina Čilė
Isoptine Belgija, Liuksemburgas, Prancūzija
Izoptomil Egiptas
Lekoptin Iranas
Manidon Ispanija
Palyuan Meksikas
Securon Didžioji Britanija
Serriten Meksikas
Unimylo Meksikas
Vasolan Japonija
Verahexal Vokietija
Veraloc Danija
Veramex Vokietija
Verapabene Austrija
Verapam Šveicarija
Verapamil Jungtinės Amerikos Valstijos, Kanada, Švedija, Vengrija, Vokietija
Verapamilo Argentina, Čilė, Ekvadoras, Kolumbija, Peru
Verpamil Malaizija, Suomija
Bibliografija   Įpurškimas   Bibliografija : Verapamil hydrochloride  
tipas leidinys
62 Žurnalas Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125.
191 Žurnalas Riley CM.
Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection.
Am J Hosp Pharm 1988 ; 45: 2079-2091.
242 Žurnalas Campbell S, Nolan PE, Bliss M, Wood R, Mayersohn M.
Stability of amiodarone hydrochloride in admixtures with other injectable drugs.
Am J Hosp Pharm 1986 ; 43: 917-921.
288 Žurnalas Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962.
300 Žurnalas Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
364 Žurnalas Johnson CE, Lloyd CW, Mesaros JL, Rubley GJ.
Compatibility of aminophylline and verapamil in intravenous admixtures.
Am J Hosp Pharm 1989 ; 46: 97-100.
371 Žurnalas Thompson DF, Stiles ML, Allen LV, Tu YH.
Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 142-145.
372 Žurnalas Johnson CE, Lloyd CW, Aviles AI, Rybarz KL.
Compatibility of premixed theophylline and verapamil intravenous admixtures.
Am J Hosp Pharm 1988 ; 45: 609-612.
398 Žurnalas Jay GT, Fanikos J, Souney PF.
Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1556-1557.
660 Žurnalas Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
706 Žurnalas Cutie MR.
Compatibility of verapamil hydrochloride with other additives.
Am J Hosp Pharm 1981 ; 38: 231.
921 Žurnalas Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
1041 Žurnalas Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951.
1045 Žurnalas Das Gupta V, Stewart KR.
Stability of dobutamine hydrochloride and verapamil hydrochloride in 0.9% sodium chloride and 5 % dextrose injections.
Am J Hosp Pharm 1984 ; 41: 686-689.
1057 Žurnalas Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1098 Žurnalas Cutie MR.
Verapamil precipitation.
Ann Intern Med 1983 ; 98: 672.
1099 Žurnalas Tucker R, Gentile JF.
Precipitation of verapamil in an intravenous line.
Ann Intern Med 1984 ; 101: 880.
1100 Žurnalas Bar-Or D, Kulig K, Marx JA, Rosen P.
Precipitation of verapamil.
Ann Intern Med 1982 ; 97: 619.
1232 Žurnalas Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1351 Žurnalas Tucker R, Gentle JF.
Precipitation of verapamil with nafcillin.
Am J Hosp Pharm 1984 ; 41: 2588.
1508 Žurnalas Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1625 Žurnalas Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Žurnalas Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1712 Žurnalas Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Žurnalas Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Žurnalas Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1803 Žurnalas Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925 Žurnalas Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1944 Žurnalas Hartman CA, Faria CE, Mago K.
Visual compatibility of bivalirudin with selected drugs.
Am J Health-Syst Pharm 2004 ; 61: 1774.
1964 Žurnalas Hartman CA, Baroletti SA, Churchill WW et al.
Visual compatibility of argatroban with selected drugs.
Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
2018 Žurnalas Veggeland T.
Visual compatibility of clonidine with selected drugs.
Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2087 Žurnalas Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
2090 Žurnalas Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2328 Laboratorija Sugammadex (Bridion®) – Résumé des caractéristiques du produits
Organon 2009
3766 Žurnalas Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3824 Žurnalas Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3934 Laboratorija Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit
GlaxoSmithKline Laboratoire 2016
4130 Žurnalas Koller AK, Krebs S, Dörje F.
Untersuchungen zur Kompatibilität von Clonidin mit häufig eingesetzen Arzneimittel auf Intensivstationen.
Pharmaceutics 2021 , 13, 21.
4603 Žurnalas Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4742 Žurnalas Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales